You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 47 No. 9, September 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Intracerebroventricular Bethanechol for Alzheimer's Disease

Variable Dose-Related Responses

Stephen L. Read, MD; John Frazee, MD; Jill Shapira, RN, MN; Cheryll Smith, PhD; Jeffrey L. Cummings, MD; Uwamie Tomiyasu, MD

Arch Neurol. 1990;47(9):1025-1030.


Abstract

• Five male patients participated in a pilot open-label study of dose-related aspects of response to intracerebroventricular bethanechol in Alzheimer's disease. No patient had remission of symptoms, but three patients improved symptomatically and on tests of memory. Improvement was evident over a restricted range of doses for each subject, and symptoms were worse at doses below and above the optimal range. There was little overlap in the range of doses producing improvement among these three. Two patients had no consistent improvement in memory, and agitation, depression, paranoia, and seizures developed during treatment. Qualitative differences and variability in dosages producing responses complicate the identification of true drug response in the treatment of Alzheimer's disease.



Author Affiliations

From the John Douglas French Center, Los Alamitos; the Departments of Psychiatry and Neurology, Harbor-UCLA Medical Center (Dr Read); Departments of Neurosurgery (Dr Frazee), Nursing (Ms Shapira), Psychology (Dr Smith), Neurology and Psychiatry (Dr Cummings), and Pathology (Dr Tomiyasu), UCLA School of Medicine and the West Los Angeles Veterans Administration Medical Center, Calif.


Footnotes

Accepted for publication November 29, 1989.

Reprint requests to John Douglas French Center, 3951 Katella Ave, Los Alamitos, CA 90720 (Dr Read).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Progression of Clinical Deterioration and Pathological Changes in Patients With Alzheimer Disease Evaluated at Biopsy and Autopsy
Di Patre et al.
Arch Neurol 1999;56:1254-1261.
ABSTRACT | FULL TEXT  

p(C) Analysis Facilitates Dementia Diagnosis
Absher et al.
Med Decis Making 1994;14:393-402.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.